ESC2015:冠脉内血栓成分与直接PCI术后慢复流的发生无明显关联

2015-09-08 李伟编译,傅向华审校 中国医学论坛报

2015欧洲心脏病学会年会(ESC2015)专题报道 背景 直接PCI后的慢复流显著影响临床短期和长期预后。慢复流发生在大约30%的STEMI患者中。许多患者相关及手术相关的因素都会影响慢复流的发生。然而,冠脉内血栓成分对慢复流的影响尚未进行深入的研究。 目的 研究STEMI患者冠脉内血栓成分与直接PCI成功率之间的关系。 方法 所有患者首次医疗接触后均给予阿司

2015欧洲心脏病学会年会(ESC2015)专题报道

背景

直接PCI后的慢复流显著影响临床短期和长期预后。慢复流发生在大约30%的STEMI患者中。许多患者相关及手术相关的因素都会影响慢复流的发生。然而,冠脉内血栓成分对慢复流的影响尚未进行深入的研究。

目的

研究STEMI患者冠脉内血栓成分与直接PCI成功率之间的关系。

方法

所有患者首次医疗接触后均给予阿司匹林、氯吡格雷及肝素预处理。直接PCI术中经血栓抽吸及切割获取的总共40份冠脉血栓标本置于扫描电镜下观察。应用软件评估术后cTFC及TMPG。

结果

术后TIMI血流3级的患者有31例,占77.5%;TMPG 3级的患者有18例,占45%,cTFC中位数为18(12-27.5)。共在323个血栓图像中分析纤维素、血小板、红细胞及白细胞成分。在不考虑血栓形成的早晚及哪种血栓成分占主体的情况下,血栓成分与cTFC及TMPG并无相关性。(见下表)

结论

冠脉内血栓成分本身并不能直接影响STEMI-直接PCI患者即刻冠脉造影的结果。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1633815, encodeId=c38416338150e, content=<a href='/topic/show?id=578d13843ad' target=_blank style='color:#2F92EE;'>#PCI术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13843, encryptionId=578d13843ad, topicName=PCI术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea4322051797, createdName=zxl736, createdTime=Thu Jan 28 20:05:00 CST 2016, time=2016-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749116, encodeId=209a1e4911688, content=<a href='/topic/show?id=843ee2425a1' target=_blank style='color:#2F92EE;'>#直接PCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72425, encryptionId=843ee2425a1, topicName=直接PCI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cef136235391, createdName=xuyu, createdTime=Fri Mar 18 02:05:00 CST 2016, time=2016-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486415, encodeId=121a148641538, content=<a href='/topic/show?id=76291384571' target=_blank style='color:#2F92EE;'>#PCI术后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13845, encryptionId=76291384571, topicName=PCI术后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ea78134582, createdName=12499e01m49暂无昵称, createdTime=Thu Sep 10 00:05:00 CST 2015, time=2015-09-10, status=1, ipAttribution=)]
    2016-01-28 zxl736
  2. [GetPortalCommentsPageByObjectIdResponse(id=1633815, encodeId=c38416338150e, content=<a href='/topic/show?id=578d13843ad' target=_blank style='color:#2F92EE;'>#PCI术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13843, encryptionId=578d13843ad, topicName=PCI术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea4322051797, createdName=zxl736, createdTime=Thu Jan 28 20:05:00 CST 2016, time=2016-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749116, encodeId=209a1e4911688, content=<a href='/topic/show?id=843ee2425a1' target=_blank style='color:#2F92EE;'>#直接PCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72425, encryptionId=843ee2425a1, topicName=直接PCI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cef136235391, createdName=xuyu, createdTime=Fri Mar 18 02:05:00 CST 2016, time=2016-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486415, encodeId=121a148641538, content=<a href='/topic/show?id=76291384571' target=_blank style='color:#2F92EE;'>#PCI术后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13845, encryptionId=76291384571, topicName=PCI术后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ea78134582, createdName=12499e01m49暂无昵称, createdTime=Thu Sep 10 00:05:00 CST 2015, time=2015-09-10, status=1, ipAttribution=)]
    2016-03-18 xuyu
  3. [GetPortalCommentsPageByObjectIdResponse(id=1633815, encodeId=c38416338150e, content=<a href='/topic/show?id=578d13843ad' target=_blank style='color:#2F92EE;'>#PCI术#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13843, encryptionId=578d13843ad, topicName=PCI术)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ea4322051797, createdName=zxl736, createdTime=Thu Jan 28 20:05:00 CST 2016, time=2016-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1749116, encodeId=209a1e4911688, content=<a href='/topic/show?id=843ee2425a1' target=_blank style='color:#2F92EE;'>#直接PCI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=72425, encryptionId=843ee2425a1, topicName=直接PCI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cef136235391, createdName=xuyu, createdTime=Fri Mar 18 02:05:00 CST 2016, time=2016-03-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1486415, encodeId=121a148641538, content=<a href='/topic/show?id=76291384571' target=_blank style='color:#2F92EE;'>#PCI术后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13845, encryptionId=76291384571, topicName=PCI术后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4ea78134582, createdName=12499e01m49暂无昵称, createdTime=Thu Sep 10 00:05:00 CST 2015, time=2015-09-10, status=1, ipAttribution=)]